TImeline

2016

6.1.2016  

Octeta Therapeutics formed by MSDC to advance the clinical development of MSDC-0602K, a new therapeutic compound currently in a Phase 2 clinical trial (the EMMINENCE™ Trial) for the treatment of nonalcoholic steatohepatitis (NASH).

2015

2015

3.18.2015  

Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease 

2014

10.23.2014  

Metabolic Solutions Development Company Appoints Robert L. Zerbe, MD to Board of Managers 

2013

9.24.2013  

Researchers present findings on key proteins in newly identified target for insulin sensitizers 


9.19.2013  

Investigational Diabetes Drug May Also Have Future As Treatment for Parksinson’s Disease 


9.9.2013  

Metabolic Solutions Development Company presents Phase 2a clinical trial results at the 14th International Conference on Alzheimer’s Drug Discovery 


5.29.2013  

Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes 


5.15.2013  

Metabolic Solutions Development Company announces publication of data describing a new drug target for diabetes 


2.7.2013  

Metabolic Solutions Development Company Awarded Funding by The Michael J. Fox Foundation 

1.24.2013  


Metabolic Solutions Development Company announces publication of Phase 2b data in “Clinical Pharmacology & Therapeutics” 

2012

2012

10.17.2012  

Metabolic Solutions Development Company CEO Stephen Benoit to Present at 2nd Annual BIO Convention in China (BIO China to be held October 24-25 in Shanghai) 


10.2.2012  

Researchers present findings on new drug target for treatment of type 2 diabetes 


9.7.2012  

Metabolic Solutions Development Company Presents Update on Ongoing Clinical Evaluation of First in Class mTOT Modulator™ in Mild Alzheimer’s Disease at 13th International Conference on Alzheimer’s Drug Discovery 


8.29.2012  

Metabolic Solutions Development Company to present at the Benzon Symposium No. 58 on Adipose Tissue in Health and Disease 


6.21.2012  

Researchers study potential new therapeutic target for Alzheimer’s disease. Medical centers in Kalamazoo and Grand Rapids referring individuals for participation in a clinical trial. 


6.9.2012  

Metabolic Solutions Development Company Identifies New Drug Target for Treatment of Type 2 Diabetes 


6.9.2012  

Metabolic Solutions Development Company Novel Insulin Sensitizer Meets Phase 2b Study Endpoints and Affirms New Mechanism of Action 


5.29.2012  

New Research Suggests Novel Insulin Sensitizer Works Through a New Mechanism to Treat Root Cause of Type 2 Diabetes 


4.11.2012  

Metabolic Solutions Development Company Adds Barbara Cannon to Science and Medical Advisory Board 


3.8.2012  

Metabolic Solutions Development Company presents Case Study: A new approach to insulin sensitizers during Phacilitate-Metabolic Leaders Forum 2012 


2.9.2012  

Researchers Study Mitochondrial Function, Potential New Therapeutic Target for Alzheimer’s Disease 


1.31.2012  

Metabolic Solutions Development Company previews latest findings on newly identified potential mechanism of action for insulin sensitization at Keystone Symposium on Pathogenesis of Diabetes: Emerging Insights into Molecular Mechanisms 

2011

12.1.2011  

Metabolic Solutions Development Company, LLC to present at Windhover’s 6th annual Therapeutic Area Partnerships meeting 

11.17.2011  

Metabolic Solutions Jandernoa Receives Spirit of Michigan Award 

10.6.2011  

Metabolic Solutions Development Company Receives $1.1 Million NIH Grant to Further Investigate MSDC-0602 for the Treatment of Fatty Liver Disease 

9.8.2011  

Metabolic Solutions Development Company presents new brown fat research at the European Association for the Study of Diabetes 

9.8.2011  

Metabolic Solutions Development Company Reports Positive Top-Line Results From 2a Trial of its Second Compound to Treat Type 2 Diabetes 

7.6.2011  

Metabolic Solutions Development Company Receives $773,000 From Alzheimers Drug Discovery Foundation To Fund Phase 2a Trial 

6.21.2011  

MSDC to Present Recent Findings at American Diabetes Association Conference 

3.29.2011  

Metabolic Solutions Development Company Launches Phase 2a Trial of its Second Compound to Treat Type 2 Diabetes 

3.7.2011  

Metabolic Solutions Development Company President and Co-Founder to Speak at Diabetes Summit 

2010

10.21.2010  

Metabolic Solutions Development Company Raises Approximately $23.5 Million; Plans to Launch Phase 2b Trial 

9.16.2010  

Metabolic Solutions Development Company to Present Research Findings to European Association for the Study of Diabetes 

6.15.2010  

Metabolic Solutions Development Company to Present Research Findings at Annual American Diabetes Association Conference 

4.8.2010  

Metabolic Solutions Development Company Named One of 50 Michigan Companies to Watch 

2009

10.12.2009  

Metabolic Solutions Development Company To Test Potential Treatment For Alzheimer’s. 

5.14.2009  

Metabolic Solutions Development Company announces preliminary results from Phase IIa clinical trial. 

4.29.2009  

Metabolic Solutions Development Company secures more than $10 Million for further development of its diabetes drug portfolio. 


2008

9.30.2008  

West Michigan drug research company set to begin major clinical trial of diabetes drug 

5.28.2008  

Dr. John Landis joins Board of Managers of Metabolic Solutions Development Coes.